Practical Valuation Methods for Early-Stage Startups
Valuing early-stage startups is more art than science. Unlike public companies with revenue, earnings, and comparable market data, pre-seed and seed-stage startups often have limited revenue, no profits, and uncertain futures. Yet every angel investment requires agreeing on a valuation, whether explicitly through a priced round or implicitly through a SAFE valuation cap.
This guide covers the valuation methods that angel investors actually use in practice, their strengths and limitations, and how to apply them to real investment decisions.
Why Traditional Valuation Fails at Early Stage
Discounted cash flow (DCF) analysis, the standard tool for valuing established companies, requires reliable projections of future cash flows. For a pre-revenue startup, these projections are essentially fiction. The range of possible outcomes is so wide that any DCF exercise produces a number that reflects the assumptions more than the reality.
Similarly, price-to-earnings ratios are meaningless when there are no earnings. Revenue multiples can work for later-stage companies with meaningful revenue, but a startup with $5,000 in monthly revenue does not lend itself to reliable multiple-based valuation.
Early-stage valuation methods acknowledge this uncertainty and use alternative frameworks that are more appropriate for the information available.
Method 1: The Berkus Method
Developed by angel investor Dave Berkus, this method assigns value based on progress across five key risk factors.
How It Works
Each factor is assigned a value of up to $500,000 (adjustable based on your market), and the sum determines the pre-money valuation.
| Factor | Addresses | Max Value |
|---|---|---|
| Sound idea | Basic value of the concept | $500,000 |
| Prototype | Technology risk reduction | $500,000 |
| Quality team | Execution risk reduction | $500,000 |
| Strategic relationships | Market risk reduction | $500,000 |
| Product rollout or sales | Production risk reduction | $500,000 |
Maximum pre-revenue valuation: $2.5 million
Strengths
- Simple and quick to apply
- Forces evaluation of specific risk categories
- Appropriate for pre-revenue companies
- Widely understood in the angel community
Limitations
- Maximum values are somewhat arbitrary
- Does not account for market size or growth potential
- May undervalue strong companies in hot markets
- The $500,000 per factor baseline needs regular adjustment for inflation and market conditions
When to Use
The Berkus method is most useful for pre-revenue companies where you need a quick sanity check on valuation. If a company with only an idea and no prototype is seeking a $5 million valuation, the Berkus method immediately highlights the disconnect.
Method 2: The Scorecard Method
The Scorecard method, developed by Bill Payne, compares the startup against a benchmark of typical pre-money valuations for the region and adjusts based on qualitative factors.
How It Works
Step 1: Determine the median pre-money valuation for angel rounds in your region and sector. In 2026, this ranges from $3 million to $8 million for most US markets.
Step 2: Score the startup against the median across weighted factors:
| Factor | Weight | Range |
|---|---|---|
| Strength of team | 30% | 0.5x - 1.5x |
| Size of opportunity | 25% | 0.5x - 1.5x |
| Product/technology | 15% | 0.5x - 1.5x |
| Competitive environment | 10% | 0.5x - 1.5x |
| Marketing/sales channels | 10% | 0.5x - 1.5x |
| Need for additional investment | 5% | 0.5x - 1.5x |
| Other factors | 5% | 0.5x - 1.5x |
Step 3: Multiply the weighted factors to get a comparison factor, then multiply by the median valuation.
Example
Median pre-money valuation: $5 million
- Team: 1.2 (above average) x 30% = 0.36
- Opportunity: 1.3 (large market) x 25% = 0.325
- Product: 1.0 (average) x 15% = 0.15
- Competition: 0.8 (crowded market) x 10% = 0.08
- Channels: 1.1 x 10% = 0.11
- Additional investment: 1.0 x 5% = 0.05
- Other: 1.0 x 5% = 0.05
Sum = 1.125
Adjusted valuation = $5M x 1.125 = $5.625 million
Strengths
- Accounts for regional market conditions
- Weights team most heavily, which aligns with research
- Systematic and reproducible
Limitations
- Requires knowing the regional median valuation
- Scoring is subjective despite the systematic framework
- Does not work well for outlier companies
Method 3: Comparable Transactions
The comparable method values a startup by reference to similar companies that recently raised capital at known valuations.
How It Works
Identify 3 to 5 companies at a similar stage, in a similar sector, and with similar traction that recently raised capital. Use their valuations as reference points, adjusting for differences in traction, team, and market conditions.
Data sources: Crunchbase, PitchBook, AngelList, and local angel network deal reports provide comparable transaction data.
Strengths
- Grounded in actual market data
- Reflects current market conditions
- Most defensible in negotiations
Limitations
- Comparable data may not be publicly available
- No two startups are truly comparable
- Market conditions change quickly, making older comparables less relevant
- Selection bias (only successful raises are reported)
When to Use
Comparables are most useful for seed-stage and later investments where there is a sufficient number of similar recent transactions to establish a meaningful range. For very early-stage companies, the comparable set is usually too thin to be reliable.
Method 4: The Risk Factor Summation Method
This method starts with a base valuation and adjusts up or down based on risk factors.
How It Works
Start with a base pre-money valuation (typically the regional median). Then evaluate 12 risk factors, adjusting the valuation by -$500,000 to +$500,000 for each:
- Management risk
- Stage of business
- Legislation/political risk
- Manufacturing risk
- Sales and marketing risk
- Funding/capital raising risk
- Competition risk
- Technology risk
- Litigation risk
- International risk
- Reputation risk
- Potential lucrative exit
Strengths
- Comprehensive risk evaluation
- Forces consideration of risk factors that other methods may overlook
- Adjustable per factor
Limitations
- Twelve factors can create analysis paralysis
- The $500,000 adjustment per factor is arbitrary
- Can produce valuations that diverge significantly from market reality
Practical Negotiation Tips
Focus on the Cap, Not the Valuation
For SAFE-based investments, the valuation cap is not a valuation. It is a maximum conversion price. A $10 million cap does not mean you believe the company is worth $10 million. It means you will convert at no worse than $10 million equivalent pricing.
Use Ranges, Not Points
Present your valuation assessment as a range. "Based on comparables and the Scorecard method, I see a reasonable pre-money range of $4 million to $6 million." This is more productive than defending a single number.
Consider the Total Raise
A $5 million valuation cap on a $500,000 raise means very different dilution than the same cap on a $2 million raise. Always consider the valuation cap in the context of total capital being raised.
Do Not Overweight Valuation
As noted in research on angel investing returns, the difference between a $5 million and $7 million valuation is less than 2x in return potential. The difference between a company that succeeds and one that fails is infinite. Spend more time on due diligence than on valuation negotiation.
Use tools like AngelHub to track investment terms and valuations across your portfolio, making it easy to compare how different entry valuations have affected your realized returns over time.
Conclusion
Early-stage startup valuation is inherently imprecise. The methods described here provide structured frameworks for arriving at a reasonable range, but they should never be confused with the precision of public market valuations. The most effective approach combines multiple methods, weights them based on the available data, and uses the result as a negotiation starting point rather than an absolute answer.
Frequently Asked Questions
Which valuation method is most commonly used by angel investors?
The Scorecard method and comparable transactions are most commonly used in combination. The Scorecard provides a structured assessment, while comparables ground the result in market reality.
How do I value a company with no revenue and no product?
The Berkus method is designed for exactly this scenario. It evaluates the value of the idea, the team, and the progress made to date. For pre-product companies, valuations should reflect the early stage: typically $1 million to $4 million pre-money in most markets.
Should I walk away from a deal if the valuation is too high?
Consider whether the valuation leaves enough upside to meet your return requirements. If you need a 10x return and the current valuation already assumes significant success, the risk-reward may not work. But do not pass on a great company over a modest valuation disagreement.
How much does traction affect early-stage valuation?
Significantly. Companies with demonstrable traction (paying customers, strong engagement metrics, growing revenue) can command 2 to 3x higher valuations than comparable companies without traction. Traction is the strongest signal of product-market fit and dramatically reduces risk.